

2017 Wisconsin Diabetes Clinical Care Recommendations At-A-Glance

This document is an encapsulated overview of the 2017 American Diabetes Association Clinical Practice Recommendations. If you would like additional information about diabetes in Wisconsin, please refer to the Chronic Disease Prevention Unit webpage: <https://www.dhs.wisconsin.gov/diabetes/index.htm> or call: 608-261-8868.

Concern	Care/Test	Frequency																										
Pre Diabetes and Prevention of Type 2 Diabetes	Check A1C test, fasting plasma glucose test, or oral glucose tolerance test	Test all adults with BMI ≥ 25 kg/m ² (≥ 23 in Asian Americans) or \geq age 45 years. If normal, retest in 3 years or less.																										
	Testing for in Children and Adolescents *Age of initiation 10 years or at onset of puberty	Overweight with 2 of the following: <ul style="list-style-type: none"> Family history of type 2 diabetes in 1st or 2nd degree relative Race/ethnicity Signs of insulin resistance or conditions associated with insulin resistance Maternal history of diabetes or gestational diabetes 																										
General Recommendations for Care	Perform diabetes-focused visit	Type 1: Every 3 months❖ Type 2: Every 3–6 months❖																										
	Review management plan; assess barriers and goals	Each focused visit; revise as needed																										
	Assess physical activity level	Each focused visit																										
	Assess lifestyle management and diabetes risk status	At each visit; refer to evidence-based prevention resources as indicated																										
	Assess nutrition/weight/growth	Each focused visit																										
Self-Management Education	Refer to a Certified Diabetes Educator (CDE) in an American Diabetes Association (ADA) recognized or American Association of Diabetes Educators (AADE) accredited program	At diagnosis, then every 6–12 months, or more as needed																										
Medical Nutrition Therapy	Refer for medical nutrition therapy (MNT) provided by a Registered Dietitian (RD), preferably a CDE	At diagnosis or first referral to RD: 3-4 visits, completed in 3-6 months; then, 1-2 hours of routine RD visits annually. RD determines additional visits per needs/goals. Medicare Part B covers 3 hours per year of MNT when referred by a physician.																										
Glycemic Control	Check A1C, general goal: < 7.0%	<ul style="list-style-type: none"> At least 2x annually in patients meeting treatment goals and have stable glycemic control Quarterly in patients with changed therapy or not meeting glycemic goals 																										
	Review goals, change in lifestyle/meals pattern, medications, side effects, and frequency of hypoglycemia	<ul style="list-style-type: none"> Each focused visit Continuous glucose monitoring (CGM) may be a supplemental tool to Self Monitored Blood Glucose (SMBG) in people with hypoglycemia unawareness and/or frequent hypoglycemic episodes 																										
	Assess self-blood glucose monitoring schedule	<ul style="list-style-type: none"> Each focused visit. Patients on multiple-dose insulin or insulin pump therapy should perform self-monitored blood glucose (SMBG) prior to meals and snacks, at bedtime, prior to exercise, when they suspect low blood glucose, and prior to critical tasks. Continuous glucose monitoring (CGM) may be a supplemental tool to Self Monitored Blood Glucose (SMBG) in people with hypoglycemia unawareness and/or frequent hypoglycemic episodes Patients not on insulin should be treated on an individual basis, as the evidence is insufficient regarding when and how often to SMBG. 																										
Cardiovascular Care	Check fasting lipid profile	Children: After age 2, then use American Academy of Pediatrics (AAP) guidelines Adults: At diagnosis, then every 5 years or more frequently as indicated																										
	Start statin with ongoing lifestyle changes	<table border="1"> <thead> <tr> <th>Age</th> <th>Risk Factors</th> <th>Statin Intensity*</th> </tr> </thead> <tbody> <tr> <td rowspan="3"><40 years</td> <td>None</td> <td>None</td> </tr> <tr> <td>ASCVD risk factor(s)</td> <td>Moderate or high</td> </tr> <tr> <td>ASCVD</td> <td>High</td> </tr> <tr> <td rowspan="3">40–75 years</td> <td>None</td> <td>Moderate</td> </tr> <tr> <td>ASCVD risk factors</td> <td>High</td> </tr> <tr> <td>ACS & LDL ≥ 50 or in patients with history of ASCVD who can't tolerate high dose statin</td> <td>Moderate + ezetimibe</td> </tr> <tr> <td rowspan="4">>75 years</td> <td>None</td> <td>Moderate</td> </tr> <tr> <td>ASCVD risk factors</td> <td>Moderate or high</td> </tr> <tr> <td>ASCVD</td> <td>High</td> </tr> <tr> <td>ACS & LDL ≥ 50 or in patients with history of ASCVD who can't tolerate high dose statin</td> <td>Moderate + ezetimibe</td> </tr> </tbody> </table>	Age	Risk Factors	Statin Intensity*	<40 years	None	None	ASCVD risk factor(s)	Moderate or high	ASCVD	High	40–75 years	None	Moderate	ASCVD risk factors	High	ACS & LDL ≥ 50 or in patients with history of ASCVD who can't tolerate high dose statin	Moderate + ezetimibe	>75 years	None	Moderate	ASCVD risk factors	Moderate or high	ASCVD	High	ACS & LDL ≥ 50 or in patients with history of ASCVD who can't tolerate high dose statin	Moderate + ezetimibe
	Age	Risk Factors	Statin Intensity*																									
	<40 years	None	None																									
ASCVD risk factor(s)		Moderate or high																										
ASCVD		High																										
40–75 years	None	Moderate																										
	ASCVD risk factors	High																										
	ACS & LDL ≥ 50 or in patients with history of ASCVD who can't tolerate high dose statin	Moderate + ezetimibe																										
>75 years	None	Moderate																										
	ASCVD risk factors	Moderate or high																										
	ASCVD	High																										
	ACS & LDL ≥ 50 or in patients with history of ASCVD who can't tolerate high dose statin	Moderate + ezetimibe																										
Check blood pressure, Adult goal: < 140/90 mmHg †	Children: Each focused visit; follow National High Blood Pressure Education Program recommendations for children and adolescents Adults: Each office visit; weight loss if overweight, DASH-style diet, Moderation of alcohol intake, increased physical activity																											
Assess smoking/tobacco use status	Each office visit; (5As: Ask, Advise, Assess, Assist, Arrange)																											

	Start aspirin therapy (unless contraindicated)	<ul style="list-style-type: none"> • Age > 50 years for most men and women with diabetes and at least one other major risk factor • Men ≤ 50 years, and women ≤ 60 years, individualized based on risk • Consider adding 75-162 mg/day
Kidney Care	Test serum creatinine to estimate GFR and chronic kidney disease (CKD) stage	Type 1: 5 years after diagnosis, then at least annually Type 2: At diagnosis, then at least annually
	ACR: Check albumin/creatinine ratio for micro albuminuria using a random urine sample: Goal <30 mg/g	Type 1: 5 years after diagnosis, then at least annually Type 2: At diagnosis, then at least annually *ACE inhibitors or angiotensin II receptor blockers reduce progression of CKD to ESRD and improve survival for hypertension with heavy albuminuria
	Hypertension diagnosis or BP >140/90 mmHg AND albumin-creatinine ratio, urine ratio greater than or equal to 300mg/g creatinine (A evidence) or 30-299 mg/g creatinine (B evidence) use ACE inhibitor or angiotensin II receptor blocker	Assess at least annually
Eye Care	Dilated and comprehensive eye exam by an ophthalmologist or optometrist	Type 1: ≥ 10 years of age: Retinal exam within 5 years of diagnosis and then annually (or once every 2 years if no retinopathy found on LAST exam) Type 2: At diagnosis, then annually;(or once every 2 years if no retinopathy found on LAST exam) Pregnant with pre-existing Type 1 or Type 2: within first trimester then second, third, and 1 year post-partum. Solely gestational diabetes: low-risk for retinopathy and not recommended for screening
Neuropathies and Foot Care	Assess/screen for neuropathy - autonomic and diabetic peripheral neuropathy (DPN)	Type 1: Five years after diagnosis, then annually Type 2: At diagnosis, then annually Type 1 and Type 2: Either pregabalin or duloxetine are recommended as initial pharmacologic treatments for neuropathic pain in diabetes
	Visual inspection of feet with shoes and socks off	Each focused visit; stress daily self-exam
	Perform comprehensive lower extremity/foot exam	At diagnosis, then annually
	Screen for peripheral artery disease (PAD) – consider ankle-brachial index (ABI)	At diagnosis, then annually
Oral Care	Simple inspections of gums and teeth for signs of periodontal disease	At diagnosis, then each focused visit
	Dental exam by general dentist or periodontal specialist	At diagnosis, then individualize based on an oral assessment and risk, as more frequent exams may be needed
Emotional and Sexual Health Care	Assess emotional health; screen for depression	Each focused visit
	Assess sexual health concerns	Each focused visit
Communicable Diseases Prevention	Provide influenza vaccine	Annually, if age ≥ 6 months
	Provide pneumococcal vaccine	Once; then per Advisory Committee on Immunization Practices
	Provide hepatitis B series	Once at diagnosis for age 19 -59 years of age; individualize for ≥ 60 years of age
	Screen for tuberculosis infection or disease	As needed
Preconception, Pregnancy and Postpartum Care	Ask about reproductive intentions/assess contraception	At diagnosis and then every visit ✧
	Provide preconception counseling/assessment that addresses the importance of glycemic control as close to normal as safely possible, ideally <6.5% A1C to reduce the risk of congenital anomalies	3–4 months prior to conception
	Counsel on the risk of development and/or progression of diabetic retinopathy	Occur before pregnancy and then within first trimester then second, third, and 1 year post-partum as indicated by degree of retinopathy
	Screen for undiagnosed type 2 diabetes in women with known risk	At first prenatal visit ✧
	Screen for gestational diabetes mellitus (GDM) in all women not known to have diabetes	At 24–28 weeks gestation ✧
	Screen for type 2 diabetes in women who had gestational diabetes mellitus (GDM)	At 4–12 weeks postpartum then at least every 3 years lifelong, using OGTT

✧ Consider more often if A1C is above the patient's goal and/or individual risk and/or complications exist, or less often if at goal and individual risk and/or complication do not exist

✧ Consider referring to provider experienced in care of women with diabetes during pregnancy

† More or less stringent blood pressure goals must be individualized if < 140/90 is not reasonable to achieve

